INT244330

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 2.71
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (ELF3) nucleolus (ELF3) nucleus (ELF3)
extracellular matrix organization (ELF3) embryo development (ELF3) cytoplasm (ELF3)
Anatomy Link Frequency
brain stem 1
kidney 1
ELF3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 10 88.12 High High
Central nervous system 17 77.60 Quite High
Dermatone 6 70.08 Quite High
Pain 41 49.64 Quite Low
Pain score 3 48.68 Quite Low
Neuropathic pain 11 42.24 Quite Low
imagery 23 41.04 Quite Low
Antihistamine 3 32.32 Quite Low
corticosteroid 2 30.88 Quite Low
fibrosis 13 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Fabry Disease 288 98.72 Very High Very High Very High
Chronic Renal Failure 37 97.64 Very High Very High Very High
Body Weight 7 97.52 Very High Very High Very High
Gauchers Disease 70 93.92 High High
Proteinuria 109 92.00 High High
Neurological Disease 3 90.40 High High
Hemorrhage 2 88.12 High High
Hypertension 6 83.84 Quite High
Left Ventricular Hypertrophy 24 80.12 Quite High
Renal Disease 71 74.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Currently, there are two forms of ERT available for the treatment of Fabry disease: (1) Replagal® (agalsidase-alfa; Shire Human Genetic Therapies, Inc., Cambridge, MA) and (2) Fabrazyme® (agalsidase-beta; Genzyme Corporation, Inc., Cambridge, MA).
Localization (forms) of ERT associated with fabry disease
1) Confidence 0.56 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.57 Pain Relevance 0
Therefore, ERT is recommended in patients who received renal transplantation to improve quality of life and to prevent cardiac and cerebrovascular complications (26, 30).
Localization (recommended) of ERT
2) Confidence 0.48 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.46 Pain Relevance 0.04
Fabry patients on ERT (22 patients) and ERT-naïve (5 patients) were studied twice (before and two days after their ERT infusion or two days after the initial measurement for those who were not on ERT).
Localization (infusion) of ERT
3) Confidence 0.43 Published 2008 Journal BMC Neurol Section Body Doc Link PMC2585087 Disease Relevance 0.19 Pain Relevance 0.04
Fabry patients on ERT (22 patients) and ERT-naïve (5 patients) were studied twice (before and two days after their ERT infusion or two days after the initial measurement for those who were not on ERT).
Localization (infusion) of ERT
4) Confidence 0.43 Published 2008 Journal BMC Neurol Section Body Doc Link PMC2585087 Disease Relevance 0.19 Pain Relevance 0.03
The European study lead by Cox-Brinkman et al (2006) also observed that ERT with HCT has been well tolerated.
Localization (tolerated) of ERT
5) Confidence 0.37 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.09 Pain Relevance 0.04
Progressive Gb3 clearance from podocytes was observed on kidney biopsies (n = 8) after 54 months of ERT (Figure 30) [309].
Localization (clearance) of ERT in kidney
6) Confidence 0.30 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.50 Pain Relevance 0
0.81), the eRT and the eSIT both had significant correlation with ?
Localization (correlation) of eRT
7) Confidence 0.28 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2528963 Disease Relevance 0 Pain Relevance 0
In patients receiving high-dose ERT, there was a consistent progression of brain stem findings, concomitant with the deterioration of auditory brain stem responses.47 Although high dose ERT may be required to control severe systemic symptoms, it does not stabilize neurological symptoms, and thus, is not recommended in neuronopathic GD.48,49
Localization (progression) of ERT in brain stem associated with gauchers disease
8) Confidence 0.26 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0.73 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox